Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Illumina (ILMN) Grows on Innovation & Strategic Partnerships

by Zacks Equity Research

Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.

    Gourav Kanti Bagchi headshot

    "Right To Try" Brings Good News for Biotech Sector: 5 Picks

    by Gourav Kanti Bagchi

    Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.

      Zacks Equity Research

      Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

      by Zacks Equity Research

      The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

        Zacks Equity Research

        Here's Why You Should Invest in Baxter International Now

        by Zacks Equity Research

        Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

          Zacks Equity Research

          ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

          by Zacks Equity Research

          Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.

            Zacks Equity Research

            Novo Nordisk's Oral Ozempic Positive in Diabetes Study

            by Zacks Equity Research

            Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

              Zacks Equity Research

              Bayer's Generic Competition, Pipeline Setback Issues Remain

              by Zacks Equity Research

              Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).

                Zacks Equity Research

                Here's Why You Should Add ResMed (RMD) to Your Portfolio Now

                by Zacks Equity Research

                With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.

                  Zacks Equity Research

                  Here's Why STERIS (STE) Stock is a Must Buy at the Moment

                  by Zacks Equity Research

                  STERIS (STE) gains ground on strategic buyouts and divestments.

                    Zacks Equity Research

                    Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                    by Zacks Equity Research

                    Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.